Publication: Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams
Issued Date
1999-01-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-28144440888
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.82, No.SUPPL. (1999)
Suggested Citation
Sarayut Supapannachart, Pongsak Khowsathit, Benjawan Patchakapati Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams. Journal of the Medical Association of Thailand. Vol.82, No.SUPPL. (1999). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25738
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams
Other Contributor(s)
Abstract
Background : Very low birth weight (VLBW, less than 1500 g) and extremely low birth weight infants (ELBW, less than 1000 g) are the premature infants that are most likely to develop symptomatic PDA. Intravenous indomethacin has proven effective in prevention of PDA in many prospective trials. This strategy will be a useful adjunctive therapy for premature infants in Thailand. Objective : To answer the following questions: 1. Will multiple doses of intravenous indomethacin, given to VLBW infants within the first day of life; effectively prevent the occurrence of symptomatic PDA? Are there any side effects or complications? 2. Will this strategy be more beneficial in ELBW? Methods and subjects : The study included thirty VLBW infants born at Ramathibodi Hospital, with birth weights ranging from 630 to 1230 g. They were randomized into 2 groups of 15 infants each. One group received 3 doses of intravenous indomethacin at the dosage of 0.2 mg/kg initially and then 0.1 mg/kg every 12 hours for 2 more-doses; the second group received a placebo. The study was performed by a double blind control. Results : Sixteen infants developed symptomatic PDA, 4 in the indomethacin group and 12 in the placebo group. The decrease in incidence of PDA is statistically significant. But when the data was analyzed separately for the VLBW and ELBW groups. The effects were only significantly different in ELBW but not yet significant in the VLBW group. There was a statistically significant difference in the incidence of severe intraventricular hemorrhage (IVH) (grade 3 or higher) in the ELBW infants. Conclusion : Intravenous indomethacin therapy given to VLBW infants with a birth weight of less than 1250 g decreased incidence of symptomatic PDA with no significant permanent side effects. The effect was markedly noticable in ELBW infants. Incidence of severe IVH was also markedly decreased in the ELBW infants who received indomethacin.